Literature DB >> 7628403

Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells.

H Dobnig1, R T Turner.   

Abstract

Previous studies demonstrated that intermittent treatment with PTH increases osteoblast number and bone formation in growing and adult rats. The cellular mechanism for this increase in osteoblast number was investigated in 16-month-old female rats. Continuous [3H]thymidine infusion over a 1-week intermittent PTH [human PTH-(1-34)] treatment period was performed to determine the percentage of newly formed osteoblasts that originate from progenitor cells. To verify increases in bone formation, we performed histomorphometry and Northern blot analysis of selected bone matrix proteins. PTH treatment resulted in dramatic increases in fluorochrome-labeled perimeter (727%), osteoid perimeter (735%), osteoblast number (626%), and steady state mRNA levels of osteocalcin (946%) and type 1 collagen (> 1000%). Autoradiographic analysis of metaphyseal sections revealed no difference in the percentage of [3H]thymidine-labeled osteoblasts between PTH- and vehicle-treated groups (4.3 +/- 1.3% vs. 5.7 +/- 2.7%, respectively). Similar changes were observed in PTH-treated ovariectomized rats. As the PTH-induced increase in osteoblast number did not require proliferation of progenitor cells we carried out an additional experiment in adult ovariectomized rats to determine the onset of PTH action. Incorporation of [3H]proline in the distal femoral epiphysis of PTH-treated adult ovariectomized rats was increased within 24 h. We conclude that the rapid PTH-induced rise in bone formation did not require cell proliferation and was most likely due to activation of preexisting bone lining cells to osteoblasts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628403     DOI: 10.1210/endo.136.8.7628403

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  138 in total

Review 1.  Stemming bone loss by suppressing apoptosis.

Authors:  J M Hock
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

2.  Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.

Authors:  R L Jilka; R S Weinstein; T Bellido; P Roberson; A M Parfitt; S C Manolagas
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

3.  Local and systemic control of the osteoblast.

Authors:  G J Strewler
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 4.  Mechanisms of bone loss and gain in untreated and treated osteoporosis.

Authors:  Juliet Compston
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

Review 5.  T cells: critical bone regulators in health and disease.

Authors:  Roberto Pacifici
Journal:  Bone       Date:  2010-05-07       Impact factor: 4.398

6.  Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis.

Authors:  Maria-Grazia Ascenzi; Vivian P Liao; Brittany M Lee; Fabrizio Billi; Hua Zhou; Robert Lindsay; Felicia Cosman; Jeri Nieves; John P Bilezikian; David W Dempster
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

Review 7.  Osteoblastogenesis regulation signals in bone remodeling.

Authors:  C Zuo; Y Huang; R Bajis; M Sahih; Y-P Li; K Dai; X Zhang
Journal:  Osteoporos Int       Date:  2012-06       Impact factor: 4.507

Review 8.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

9.  Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Clare C Thomas; Ernestina Schipani; F Richard Bringhurst; Henry M Kronenberg
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 10.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.